A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab

NCT06145373 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia A

Interventions

DRUG: Fitusiran (SAR439774)
BIOLOGICAL: Clotting factor concentrates (CFC) or bypassing agents (BPA)
BIOLOGICAL: Antithrombin concentrate (ATIIIC)
BIOLOGICAL: Emicizumab

Sponsor

Sanofi